Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444245 | 1.00 | CYP3A4 (0.38) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6442635 | 0.95 | LMNA (0.39) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6446801 | 0.95 | LMNA (0.39) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6443811 | 0.93 | LMNA (0.42) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6445456 | 0.93 | LMNA (0.42) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6443061 | 0.93 | MEN1 (0.38) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6444181 | 0.93 | MEN1 (0.38) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6442035 | 0.93 | CYP3A4 (0.41) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6443299 | 0.93 | CYP3A4 (0.41) | CYP3A4LMNANR1I2NR3C1CYP17A1 | |
| SCHEMBL6444372 | 0.89 | KMT2A (0.39) | CYP3A4LMNANR1I2NR3C1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159366-A1 | Pharmaceutical compositions and treatment methods - 8 | BIOVIE INC. | 2005-07-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159366-A1 | Pharmaceutical compositions and treatment methods - 8 | HSD17B7, NR5A1, HSD3B1 | CYP3A4 144/4885LMNA 4071/4885NR1I2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.